Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study
42.8% ORR in multiple myeloma at the 75mCi total body dose42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) […]